dc.rights.license | CC-BY-NC-ND | |
dc.contributor.advisor | Zaiss, D. | |
dc.contributor.advisor | Sijts, A. | |
dc.contributor.author | Yilmaz, V. | |
dc.date.accessioned | 2012-08-24T17:01:06Z | |
dc.date.available | 2012-08-24 | |
dc.date.available | 2012-08-24T17:01:06Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/14945 | |
dc.description.abstract | Cancer is the leading cause of death in economically developed countries and the conventional anti-cancer therapies fail to meet the criteria of an ideal, safe and highly effective therapy especially against the metastatic cancer types. Cancer immunotherapy is an up-coming anti-cancer therapy that uses the patient’s own immune system to target and kill the cancer cells. There are several different strategies and approaches to the cancer immunotherapy in respect to the diverse hallmarks of cancer. While some of these immunotherapeutic agents are approved and made their way into practice, some needs further development and assessment in trials. This study aims to review the already accepted and newly developing immunotherapies against cancer and also to shed light on the issues associated with cancer immunotherapy that determine its failures, successes and future in clinical studies and medical practice. | |
dc.description.sponsorship | Utrecht University | |
dc.format.extent | 867161 bytes | |
dc.format.mimetype | application/pdf | |
dc.language.iso | en | |
dc.title | Cancer Immunotherapy | |
dc.type.content | Master Thesis | |
dc.rights.accessrights | Open Access | |
dc.subject.keywords | Cancer, Immunotherapy, cancer immunology, cancer treatment | |
dc.subject.courseuu | Molecular and Cellular Life Sciences | |